Key Takeaways
- • David Einhorn's Greenlight Capital established positions in Chemours (CC) in Q2 2019 as a traditional value investment thesis, with the hedge fund characterizing its stake as "medium-sized" relative to smaller positions in Dillard's and Scientific Games.
- • Chemours stock demonstrated significant upside during Einhorn's holding period, advancing from $22.09 to $38.50 during Q1 2017, reflecting the value realization thesis underlying the investment.
- • Greenlight Capital made new bets on Chemours during the second quarter, signaling continued conviction in the chemical company despite broader market dynamics.
- • The investment represents Einhorn's characteristic deep-value approach, grounded in fundamental analysis of undervalued equities rather than thematic or momentum-driven positioning.
Summary
David Einhorn's Greenlight Capital initiated a position in Chemours Company (CC), the specialty chemicals manufacturer, during the second quarter of 2019 as part of a disciplined value-investing strategy. Einhorn characterized the stake as "medium-sized" within the fund's overall portfolio, positioning it as a core conviction trade alongside smaller positions established in retailers Dillard's and gaming company Scientific Games.
The Chemours investment reflects Einhorn's traditional value methodology—identifying undervalued businesses trading below intrinsic value with catalysts for multiple expansion or operational improvement. Greenlight made additional bets on the chemical company during subsequent quarters, indicating sustained conviction in the thesis. Historical performance data from the holding period demonstrates the thesis's merit: during Q1 2017, Chemours stock advanced from $22.09 to $38.50, representing a 74% appreciation that illustrates the value realization potential Einhorn identified in the security.
As of March 2026, Greenlight Capital's portfolio composition reflects a diversified approach across multiple sectors, with top holdings including Green Brick Partners (19.12% allocation), Fluor Corporation (6.94%), and PG&E Corporation (3.65%), among others. The Chemours position represents Einhorn's willingness to maintain exposure to cyclical, capital-intensive industries when valuation dislocations create asymmetric risk-reward opportunities. The investment underscores the hedge fund's continued focus on fundamental security analysis and patient capital deployment in neglected equity opportunities.
The Chemours investment reflects Einhorn's traditional value methodology—identifying undervalued businesses trading below intrinsic value with catalysts for multiple expansion or operational improvement. Greenlight made additional bets on the chemical company during subsequent quarters, indicating sustained conviction in the thesis. Historical performance data from the holding period demonstrates the thesis's merit: during Q1 2017, Chemours stock advanced from $22.09 to $38.50, representing a 74% appreciation that illustrates the value realization potential Einhorn identified in the security.
As of March 2026, Greenlight Capital's portfolio composition reflects a diversified approach across multiple sectors, with top holdings including Green Brick Partners (19.12% allocation), Fluor Corporation (6.94%), and PG&E Corporation (3.65%), among others. The Chemours position represents Einhorn's willingness to maintain exposure to cyclical, capital-intensive industries when valuation dislocations create asymmetric risk-reward opportunities. The investment underscores the hedge fund's continued focus on fundamental security analysis and patient capital deployment in neglected equity opportunities.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.